Syndax Pharmaceuticals Announces Three Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting

On April 14, 2020 Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported three presentations at the upcoming 2020 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting being held April 27 – 28, 2020 (Press release, Syndax, APR 14, 2020, View Source [SID1234556310]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Special Session Details

Title: A first-in-class Menin-MLL1 antagonist for the treatment of MLL-r and NPM1 mutant leukemias
Presenter: Gerard McGeehan, Ph.D.
Session: New Drugs on the Horizon
Session Date and Time: Mon., April 27, 2020; 4:54 p.m. – 5:14 p.m. ET

The New Drugs on the Horizon session will feature discussions of innovative small molecules and biologics that have recently entered Phase I clinical trials. The session will include a presentation on SNDX-5613, the Company’s oral Menin inhibitor, including a brief update of the ongoing AUGMENT-101 trial.

Oral Presentation Details

Title: A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 monotherapy in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors
First author: Nilo Azad, M.D.
Session: Phase I Clinical Trials
Abstract Number: CT149
Session Date and Time: Mon., April 27, 2020; 9:00 a.m. – 6:00 p.m. ET

Title: A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 in combination with durvalumab in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors
First author: Anthony W. Tolcher, M.D.
Session: Phase I Trials in Progress
Abstract Number: CT242
Session Date and Time: Mon., April 27, 2020; 9:00 a.m. – 6:00 p.m. ET

Session information is available online via the Annual Meeting Itinerary Planner through the AACR (Free AACR Whitepaper) website at www.aacr.org.